AVXL - ANAVEX LIFE SCIENCES CORP.

What This Filing Is

This is a DFAN14A (soliciting material) filed by PVG Asset Management Corporation, an activist shareholder group, seeking to replace Anavex Life Sciences Corp.'s board of directors with PVG's own slate of six director candidates at the company's 2026 annual meeting.

Background

Anavex Life Sciences Corp. (AVXL) is a biopharmaceutical company developing treatments for Alzheimer's disease and other conditions. The stock has declined approximately 70% from its 52-week high of $10.40, trading near $3.12. PVG cites a series of corporate governance and operational concerns that it believes have destroyed shareholder value, including the firing of the CEO on April 30, 2026, without public explanation, and the company's failure to file quarterly earnings reports on time — including an impending missed deadline of August 15, 2026.

What the Filer Is Demanding

• Election of PVG's slate of six director candidates to replace the current Anavex board at the 2026 annual meeting
• Filing was made using a GOLD universal proxy card
• PVG is soliciting proxies from Anavex shareholders in support of these director nominees and any other proposals to be presented at the annual meeting

Key Arguments Made

• Missed earnings deadlines: Anavex has missed at least one quarterly earnings report and is about to miss a second, due August 15, 2026; PVG states "there is no excuse for missing reporting earnings on time"
• Delisting risk: PVG warns the board "seriously risks having the stock delisted" due to non-compliance with reporting requirements
• CEO termination concerns: The CEO was fired "for cause" on April 30, 2026, with no public explanation provided to investors; the replacement CEO reportedly has no prior CEO experience
• Mass departures: PVG states that "many of the very important players at the company were also fired"
• Stock performance: The stock declined over 50% from its yearly high at the time of the video (July 2026); the stock was described as "approaching the cash on the balance sheet"
• Strategic uncertainty: PVG alleges the company may be changing direction without communicating any update to investors
• Drug potential acknowledged: A former employee contacted PVG to confirm the drug works but stated a Phase 3 trial is needed with improved methodology, including more brain imaging to demonstrate efficacy; PVG characterizes the Alzheimer's drug candidate as having "massive potential"
• Board inadequacy: PVG states "this company will not make it with this team"

Meeting Date

Not found in filing (referenced as the "2026 annual meeting" without a specific date).

Activist Identity

PVG Asset Management Corporation

• Affiliated individuals (proxy participants): Patrick S. Adams, Jason Kolbert, Ralf von Ziegesar, Rene Mora, John Boris, Curtis Hogue
• Stated ownership: As of the date of the amended preliminary proxy statement, participants collectively owned 327,344 shares of Anavex common stock, representing approximately 0.36% of outstanding shares
• Proxy solicitor: InvestorCom, 1055 Washington Boulevard, Suite 520, Stamford, CT 06901

Status

This filing is preliminary soliciting material (DFAN14A) submitted in connection with an amended preliminary proxy statement filed on August 18, 2026. No definitive proxy statement has been filed yet. The proxy contest is at an early stage, and PVG has indicated it intends to file a definitive proxy statement and accompanying GOLD proxy card with the SEC at a future date.